6.735
Schlusskurs vom Vortag:
$7.08
Offen:
$7.12
24-Stunden-Volumen:
52,712
Relative Volume:
0.35
Marktkapitalisierung:
$58.40M
Einnahmen:
$137.27M
Nettoeinkommen (Verlust:
$-123.57M
KGV:
-0.6151
EPS:
-10.95
Netto-Cashflow:
$-102.89M
1W Leistung:
-12.30%
1M Leistung:
+67.54%
6M Leistung:
+5.73%
1J Leistung:
-37.00%
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Firmenname
Karyopharm Therapeutics Inc
Sektor
Branche
Telefon
617-658-0600
Adresse
85 WELLS AVENUE, NEWTON, MA
Vergleichen Sie KPTI mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
KPTI
Karyopharm Therapeutics Inc
|
6.735 | 58.79M | 137.27M | -123.57M | -102.89M | -10.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-16 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2025-07-11 | Fortgesetzt | H.C. Wainwright | Buy |
2023-01-19 | Eingeleitet | Piper Sandler | Overweight |
2022-11-04 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2022-02-09 | Hochstufung | JP Morgan | Underweight → Neutral |
2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
2021-08-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2021-08-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2020-07-02 | Eingeleitet | Morgan Stanley | Overweight |
2020-03-04 | Eingeleitet | Barclays | Overweight |
2020-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
2019-07-23 | Hochstufung | JP Morgan | Neutral → Overweight |
2019-07-05 | Bestätigt | H.C. Wainwright | Buy |
2019-07-05 | Bestätigt | Robert W. Baird | Outperform |
2019-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
2019-02-28 | Bestätigt | BofA/Merrill | Underperform |
2019-02-27 | Herabstufung | BofA/Merrill | Neutral → Underperform |
2019-01-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
2018-12-03 | Eingeleitet | B. Riley FBR | Buy |
2018-11-09 | Hochstufung | Wedbush | Neutral → Outperform |
2018-05-24 | Herabstufung | Wedbush | Outperform → Neutral |
2018-04-02 | Fortgesetzt | Leerink Partners | Outperform |
2017-11-15 | Fortgesetzt | H.C. Wainwright | Buy |
2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
2016-09-08 | Bestätigt | H.C. Wainwright | Buy |
2016-08-30 | Hochstufung | Jefferies | Hold → Buy |
2016-08-18 | Eingeleitet | H.C. Wainwright | Buy |
2016-06-28 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten
Analyzing recovery setups for Karyopharm Therapeutics Inc. investorsWeekly Trend Summary & Community Consensus Stock Picks - Newser
Published on: 2025-09-04 22:09:45 - Newser
Is Karyopharm Therapeutics Inc. in a long term uptrendTrade Exit Report & Real-Time Volume Surge Alerts - khodrobank.com
Published on: 2025-09-04 06:44:04 - Newser
Automated trading signals detected on Karyopharm Therapeutics Inc.2025 Price Targets & Reliable Breakout Stock Forecasts - Newser
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
Is Karyopharm Therapeutics Inc. gaining market shareCEO Change & Scalable Portfolio Growth Methods - khodrobank.com
Can Karyopharm Therapeutics Inc. recover in the next quarterInsider Buying & Real-Time Buy Signal Notifications - Newser
Strategies to average down on Karyopharm Therapeutics Inc.July 2025 Earnings & Safe Swing Trade Setups - Newser
Will Karyopharm Therapeutics Inc. benefit from rate cutsJuly 2025 News Drivers & Comprehensive Market Scan Reports - khodrobank.com
What machine learning models say about Karyopharm Therapeutics Inc.Trade Exit Summary & Weekly High Potential Alerts - Newser
Is now the right time to enter Karyopharm Therapeutics Inc.Weekly Risk Report & Fast Gain Swing Alerts - khodrobank.com
How to use a screener to detect Karyopharm Therapeutics Inc. breakoutsStock Surge & Free Technical Confirmation Trade Alerts - Newser
Karyopharm Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Using data tools to time your Karyopharm Therapeutics Inc. exitForecast Cut & Stock Market Timing Techniques - Newser
Is Karyopharm Therapeutics Inc. benefiting from innovation trends2025 Volatility Report & Capital Protection Trading Alerts - خودرو بانک
What candlestick patterns are forming on Karyopharm Therapeutics Inc.Market Rally & AI Enhanced Execution Alerts - Newser
Karyopharm Therapeutics Inc. stock daily chart insightsQuarterly Market Review & Accurate Buy Signal Notifications - Newser
What high frequency data says about Karyopharm Therapeutics Inc.Weekly Stock Recap & Accurate Entry/Exit Alerts - Newser
What are Karyopharm Therapeutics Inc.’s recent SEC filings showing2025 Market Overview & Safe Entry Momentum Tips - khodrobank.com
Can you recover from losses in Karyopharm Therapeutics Inc.July 2025 EndofMonth & Accurate Entry/Exit Alerts - Newser
Analyzing Karyopharm Therapeutics Inc. with multi timeframe chartsQuarterly Growth Report & Accurate Trade Setup Notifications - Newser
Market Outlook: What are Karyopharm Therapeutics Inc.’s recent SEC filings showingLayoff News & Community Supported Trade Ideas - khodrobank.com
How Karyopharm Therapeutics Inc. stock reacts to Fed policy changesBull Run & Real-Time Volume Spike Alerts - Newser
Published on: 2025-09-01 11:39:57 - beatles.ru
What momentum shifts mean for Karyopharm Therapeutics Inc.2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - Newser
Forecasting Karyopharm Therapeutics Inc. price range with options dataMarket Volume Report & High Accuracy Trade Signal Alerts - Newser
How to read the order book for Karyopharm Therapeutics Inc.Market Sentiment Report & Reliable Price Action Trade Plans - Newser
Will Karyopharm Therapeutics Inc. stock go up soon2025 Risk Factors & Low Risk High Reward Ideas - Newser
Can Karyopharm Therapeutics Inc. hit a new high this monthChart Signals & High Win Rate Trade Alerts - Newser
Trend analysis for Karyopharm Therapeutics Inc. this weekJuly 2025 Catalysts & Weekly Breakout Stock Alerts - Newser
Multi factor analysis applied to Karyopharm Therapeutics Inc.July 2025 Drop Watch & Daily Stock Trend Reports - Newser
Using AI based signals to follow Karyopharm Therapeutics Inc.Dividend Hike & Expert Approved Momentum Trade Ideas - Newser
Karyopharm Therapeutics Inc. stock prediction for this weekTrade Volume Report & Advanced Swing Trade Entry Plans - Newser
Is Karyopharm Therapeutics Inc. trending in predictive chart modelsPortfolio Gains Summary & Free Community Supported Trade Ideas - Newser
Is a relief rally coming for Karyopharm Therapeutics Inc. holdersPortfolio Risk Report & Safe Entry Trade Signal Reports - Newser
Finanzdaten der Karyopharm Therapeutics Inc-Aktie (KPTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Karyopharm Therapeutics Inc-Aktie (KPTI) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Abate Kristin | Chief Accounting Officer |
Jul 22 '25 |
Sale |
4.00 |
238 |
952 |
9,475 |
Paulson Richard A. | President and CEO |
May 06 '25 |
Sale |
7.12 |
236 |
1,680 |
82,503 |
Rangwala Reshma | EVP & Chief Medical Officer |
Apr 23 '25 |
Sale |
6.17 |
419 |
2,585 |
28,853 |
Paulson Richard A. | President and CEO |
Apr 04 '25 |
Sale |
3.74 |
245 |
916 |
82,739 |
Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
Mar 04 '25 |
Sale |
6.29 |
3,445 |
21,669 |
34,314 |
Paulson Richard A. | President and CEO |
Mar 04 '25 |
Sale |
6.29 |
11,694 |
73,555 |
82,984 |
Rangwala Reshma | EVP & Chief Medical Officer |
Mar 04 '25 |
Sale |
6.29 |
3,587 |
22,562 |
29,272 |
Poulton Stuart | EVP, Chief Development Officer |
Mar 04 '25 |
Sale |
6.29 |
3,548 |
22,317 |
27,414 |
Mano Michael | SVP, General Counsel&Secretary |
Mar 04 '25 |
Sale |
6.29 |
2,793 |
17,568 |
21,047 |
Poulton Stuart | EVP, Chief Development Officer |
Feb 18 '25 |
Sale |
0.63 |
5,914 |
3,726 |
320,714 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):